Negative sentiments due to the closure of Batang Kali - Genting road. Alzheimer drugs would take sometime to materialise. We better hope the new PM can rebalance the green wave and secularism of the country within the next five years so that the casino can continue to operate without interruption and scepticism.
Just attended Taurx AGM webcast couple of days ago. Full focus on securing regulatory approvals for 2023. 2024 IPO valuation largely depends on how many countries' approvals Taurx can obtain. For Mild Cognitive Impairment patients at 18 month duration, Lecanemab slows down cognition by only 27% but HMTM can fully reverse cognition decline and improve by 21%. 27% vs 121%. Early AD can be cured by HMTM with zero side effects.
Aiyo amateur @DreamMakers what do you know abt the AD field? Have you heard of CMA? Do you even know that Biogen's Aduhelm (F.K.A Aducanumab) did not even finish their clinical trials but was approved by FDA?
@AngTayKor, did TauRX mention when they would apply for regulatory approval for their HMTM? and when they would target the first regulatory approval to be obtained from US FDA, UK or Canada authority??
UK n UAE easier to score. Then use them as reference point to score for FDA n EMA but all will move concurrently in year 2023. HMTM is exactly what world need to halt AD pandemic. Cheap oral drug with zero side effects that can reverse or halt AD progression. You saw the power of HMTM. 16mg at 18mth still can see reversal for mci patients. Wtf is lecanemab’s 27% slowdown that comes with multiple death cases??? Lecanemab is rubbish.
We spent a lot of time trying out 39 different blue compounds try to get a palatable drug with blue pee effect but all failed. Hence bopian went to use super low dose MTC formula of methylene blue.
@neohts, we already saw the phase 3 results. At 18 mths, HMTM's MCI patient group saw complete reversal of cognition decline plus improvement of 21% compared to start of trial with zero side effects. Compare this to lecanemab’s 27% slowdown with 21% patients experiencing potentially fatal side effects.
Eisai did trial for mci patients. Now applying for both mci n mild group of patients. The targeted patient market increased dramatically. If they did trial on mild patients, the trial will not see statistical significance because the expected slowdown will be by abt half of what we saw for mci patients 27% . Very cunning playing around the grey area of patient group. Regulators n CMS insurance shd be very firm just limit lecanemab to mci patients since their trial is on mci patients only.
Lets have a hypothetical example of what is the meaning of a 27% slowdown. 27% slowdown in decline means if the base score for mci patients at start of trial is 20, placebo group/ADNI score at 18mth drop to 18. Lecanemab patients drop to abt 18.5. Thats approximately 27% slowdown in decline out of the 2 point drop.
HMTM mci patients totally halt the decline plus improve score by 21% from baseline start. HMTM patients score is 24. A 20% improvement from 20 points. This is a reversal of disease progression, to real improvement. This drug not only totally halts AD progression in decline, to an improvement. It is a cure for AD!
We need to see price around 5 before we can say it is on uptrend. Last year it was 5.37 when prospects were not clear. Right now it price is stuck badly whilst other sectors are moving forward. Political risk has gone. Just does not make sense!
We need to see price around 5 before we can say it is on uptrend. Last year it was 5.37 when prospects were not clear. Right now it price is stuck badly whilst other sectors are moving forward. Political risk has gone. Just does not make sense!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Zhuge_Liang
2,533 posts
Posted by Zhuge_Liang > 2022-12-23 12:05 |
Post removed.Why?